



## **Banyu and Santen Announce Co-Promotion Agreement for Combination Ophthalmic Solution, Treatment for Glaucoma and Ocular Hypertension**

March 2, 2010-- Banyu Pharmaceutical, Co., Ltd. (Tokyo, Japan) (hereafter "Banyu") and Santen Pharmaceutical, Co., Ltd. (Osaka, Japan) (hereafter "Santen") announced that they have concluded an agreement for co-promotion in Japanese domestic territory, for dorzolamide hydrochloride/ timolol maleate combination ophthalmic solution, a treatment agent for glaucoma and ocular hypertension, which is now under review for manufacturing and marketing approval by Banyu (hereafter, "Co-promotion Agreement").

Under the terms of this agreement, Banyu and Santen will start co-promotion activities after MHLW (Japanese regulatory agency) grants approval for the new dorzolamide hydrochloride/ timolol maleate combination ophthalmic solution. Banyu will retain the manufacturing/ marketing approval, and Santen will gain distribution rights.

Banyu has been striving to contribute towards treatment of glaucoma and ocular hypertension through sales of TIMOPTOL XE<sup>®1</sup>, TIMOPTOL<sup>®1</sup> and TRUSOPT<sup>®1</sup> until now. By entering into this co-promotion agreement, Banyu wishes to strengthen the drug information services for dorzolamide hydrochloride/ timolol maleate combination ophthalmic solution and further reinforce its glaucoma and ocular hypertension treatment segment. By doing so, Banyu intends to further contribute towards the doctors and patients.

Santen already has several glaucoma treatment drugs on the market, including "TAPROS<sup>®2</sup> Ophthalmic Solution", "DETANTOL<sup>®3</sup> Ophthalmic Solution", "TIMOPTOL<sup>®1</sup> XE Ophthalmic Solution", "TIMOPTOL<sup>®</sup> Ophthalmic Solution" and "RESCULA<sup>®4</sup> Ophthalmic Solution". The addition of this new combination ophthalmic solution will enhance the Santen product lineup in this disease field, will provide more treatment choices for medical care professionals, and further contribute to improving the QOL (quality of life) for patients with glaucoma and ocular hypertension.

**About dorzolamide hydrochloride/ timolol maleate ophthalmic solution;**

- It is a combination ophthalmic solution product which contains; Dorzolamide hydrochloride ophthalmic solution (a registered trademark of Banyu: TRUSOPT<sup>®1</sup>) 1%, a carbonic hydrase inhibitor (CAI) formulation, and Timolol maleate ophthalmic solution (registered trademarks of Banyu and Santen: TIMOPTOL<sup>®1</sup>) 0.5%, a beta-blocker.
- Banyu filed for manufacturing and marketing approval with MHLW for the Dorzolamide hydrochloride/ Timolol maleate combination ophthalmic solution in June, 2008. As of this date, it has not yet been approved or launched.
- Since its launch in 1998, Dorzolamide hydrochloride/ Timolol maleate combination ophthalmic solution is currently being prescribed in about 90 countries such as the United States, and is the most widely used combination ophthalmic solution in the world.

The following brand names are registered trademarks.

®1: "TIMOPTOL", "TRUSOPT", Registered Trademarks of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, N.J., U.S.A., ®2: "TAPROS" (Santen), ®3: "DETANTOL" (Eisai Co., Ltd.), ®4: "RESCULA" (R-Tech Ueno, Ltd.)

<Contact information>

Banyu Pharmaceutical, Co., Ltd.  
Communications Office  
KITANOMARU SQUARE, 1-13-12,  
Kudan-kita, Chiyoda-ku,  
Tokyo 102-8667, Japan  
TEL: +81-3-6272-1001 FAX : +81-3-6238-9136

Santen Pharmaceutical, Co., Ltd.  
Corporate Communication Group  
9-19, Shimoshinjo 3-chome,  
Higashiyodogawa-ku,  
Osaka 533-8651, Japan  
TEL: +81-6-6321-9957 FAX : +81-6-6321-8400

## References

### 【About Banyu】

1. Established : 1915
2. Headquarters : KITANOMARU SQUARE, 1-13-12, Kudan-kita, Chiyoda-ku, Tokyo 102-8667, Japan
3. Paid-in Capital : ¥44.329 million (As of December, 2008)
4. Representative : Mark Timney President and Representative Director
5. Number of Employees : Approx. 3,300 (As of April 1, 2009)
6. Net sales : ¥202.3 billion (As of December, 2008)

For details, please visit the following website [www.banyu.co.jp](http://www.banyu.co.jp)

### 【About Santen】

7. Established : 1890
8. Headquarters : 9-19, Shimoshinjo 3-chome, Higashiyodogawa-ku, Osaka 533-8651, Japan
9. Paid-in Capital : ¥6.524 million (As of December 31, 2009)
10. Representative : Akira Kurokawa President and CEO
11. Number of Employees : 2,730 (Consolidated) (As of December 31, 2009)
12. Net sales : ¥101.6 billion (As of March 2009)

For details, please visit the following website <http://www.santen.co.jp>